Company Overview
Encompass Health Corporation operates inpatient rehabilitation hospitals across the United States and Puerto Rico, delivering specialized rehabilitative treatment that utilizes advanced technology and therapy to assist patients recovering from major injuries or illnesses in regaining their functional capabilities. The company functions within the Healthcare sector, specifically the Medical Care Facilities industry, which positions it as a provider of essential post-acute care services rather than primary or acute hospital care. Its financial scale is substantial, with a market capitalization of $9.82B and an annual revenue of $5.94B TTM, supported by a workforce of 24,611 employees. These valuation and revenue figures indicate that Encompass Health is a significant player in the rehabilitation landscape, commanding a market presence that reflects established operational reach and a solidified position within the competitive medical care facilities sector.
Financial Health
The company reported revenue of $5.94B and net income of $565.70M over the trailing twelve months, with EBITDA reaching $1.38B; the significant gap between the total revenue and net income reveals a cost structure where operating expenses, including cost of goods sold, administrative costs, and depreciation, consume a substantial portion of gross receipts before arriving at the bottom line. Free cash flow stands at $296.79M, which provides the company with financial flexibility to service its obligations, return capital to shareholders, or invest in operational improvements without relying solely on external financing. The profitability analysis shows a gross margin of 43.2%, an operating margin of 18.3%, and a profit margin of 9.5%, indicating that while the company retains a healthy portion of revenue after direct costs, the operating margin suggests significant overheads are absorbed before reaching net earnings. Regarding liquidity and leverage, total cash on hand is $72.20M while total debt stands at $2.71B, resulting in a debt-to-equity ratio of 82.85, which characterizes the balance sheet as highly leveraged given the disparity between interest-bearing liabilities and liquid assets. Short-term liquidity is assessed via a current ratio of 1.08, indicating that the company holds slightly more current assets than current liabilities, suggesting a marginally comfortable but tight ability to meet short-term obligations. Return on Equity is 24.8% and return on assets is 9.7%, metrics that reveal management is highly effective at generating returns on shareholder capital relative to the total asset base, despite the heavy debt load.
Valuation Assessment
The valuation metrics present a trailing P/E ratio of 17.58 and a forward P/E of 15.07, implying that the market expects earnings growth that will eventually drive the stock price closer to the forward multiple, as the lower forward P/E suggests analysts anticipate higher profitability in the coming period compared to the current trailing twelve months. The price-to-book ratio is 4.00, which indicates that the market values the company at four times its book value, suggesting a significant premium over the net asset value that investors are willing to pay based on expected future cash flows and brand intangibles. Alternative valuation metrics include a price-to-sales ratio of 1.65 and an EV/EBITDA of 9.54, which suggest the company is valued moderately relative to its sales volume and earnings power before interest, taxes, depreciation, and amortization, providing a different perspective on value than the P/E alone. The stock has a 52-week high of $127.99 and a 52-week low of $92.77; assuming the current trading price is near the midpoint of this range, the stock is trading roughly 17% below the 52-week high and 15% above the 52-week low, reflecting recent volatility within a defined band. The beta is 0.56, which means the stock exhibits lower price volatility relative to the broader market, moving less dramatically than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth stands at 9.9% year-over-year while earnings growth reaches 21.2% year-over-year, indicating that earnings are growing significantly faster than revenue, which implies improved operational leverage, cost efficiencies, or a shift in the mix of services provided that enhances profitability on a per-unit basis. For this dividend payer, the dividend yield is 0.8% with a payout ratio of 13.0%, indicating that the payout is highly sustainable given the low percentage of earnings distributed to shareholders and the retention of the majority of net income for reinvestment. Since the payout ratio is only 13.0%, the company retains a vast majority of its earnings, allowing for aggressive reinvestment into growth initiatives rather than relying on dividends as a primary return mechanism. The overall growth and income profile is characterized by robust double-digit earnings expansion, a conservative dividend approach that preserves capital, and a low-beta stock that offers income with reduced volatility relative to the broader healthcare sector.